A single gene therapy injection that could eliminate years of anti-VEGF eye injections is now in its first Phase 3 test: 4D Molecular Therapeutics announced September 28 that patients are enrolling across multiple sites in 4SIGHT, its global Phase 3 trial of 4D-150 in diabetic macular edema. The trial targets 514 treatment-naïve DME patients, and its design frames the central clinical question plainly: can a one-time intravitreal dose of a dual-transgene AAV vector hold its own against the monthly or bimonthly anti-VEGF injections that currently define standard care?
The Phase 3 launch rides on two years of SPECTRA data that, for a gene therapy program, look unusually clean. In 22 patients, 4D-150 produced no intraocular inflammation at any timepoint, no ocular serious adverse events, and no hypotony, endophthalmitis, vasculitis, choroidal effusions, or retinal artery occlusions. That safety profile matters because intraocular inflammation has historically been the mechanism that ended or constrained AAV retinal programs. SPECTRA also showed durable clinical activity through 24 months, though the full efficacy numbers from the 2-year readout were not detailed in the 8-K filing.
4D-150 uses 4DMT’s proprietary R100 AAV variant, engineered through the company’s Therapeutic Vector Evolution platform, and delivers two transgenes simultaneously: one targeting VEGF and one targeting PDGF-B, the pairing meant to address the vascular and fibrotic components of retinal neovascular disease together. DME is 4D-150’s second large retina indication; the company previously moved the same construct into Phase 3 for wet age-related macular degeneration. Running two Phase 3 programs with the same vector and overlapping manufacturing requirements creates real execution risk, but it also means a single safety signal in either trial now has implications for both.
The number to track from 4SIGHT is not enrollment speed but durability at the primary endpoint: how many patients in the 4D-150 arm remain free of rescue injections at 52 weeks, and whether that fraction holds through any longer follow-up the protocol specifies. That figure will determine whether a one-time treatment can realistically compete with the established, if burdensome, efficacy of repeated anti-VEGF dosing in DME.
Source link: https://www.sec.gov/Archives/edgar/data/1650648/000119312526403424/d147828d8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
